TherapeuticsMD (TXMD) Research & Development (2011 - 2022)

TherapeuticsMD (TXMD) has reported Research & Development for 12 consecutive years, with $19.1 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Research & Development fell 36.25% year-over-year to $19.1 million; the trailing twelve-month figure through Sep 2022 stood at $83.7 million (down 25.39% YoY), and the FY2021 full-year result was $108.2 million, down 7.57% from the prior year.
• Research & Development slipped to $19.1 million in Q3 2022 per TXMD's latest filing, from $23.7 million in the prior quarter.
• Across five years, Research & Development topped out at $98.9 million in Q4 2019 and bottomed at $3.3 million in Q1 2020.
• Historically, Research & Development has averaged $20.7 million across 5 years, with a median of $19.1 million in 2022.
• The sharpest annual moves came in 2019 and 2020: Research & Development soared 1364.06% in 2019, then plunged 73.71% in 2020.
• Over 5 years, Research & Development stood at $6.8 million in 2018, then jumped by 1364.06% to $98.9 million in 2019, then slumped by 73.71% to $26.0 million in 2020, then decreased by 15.36% to $22.0 million in 2021, then fell by 13.06% to $19.1 million in 2022.
• According to Business Quant data, Research & Development over the past three periods registered $19.1 million, $23.7 million, and $18.9 million for Q3 2022, Q2 2022, and Q1 2022 respectively.